De Filippi P.,University of Pavia |
Saeidi K.,University of Pavia |
Ravaglia S.,Irccs Neurological Institute C Mondino |
Dardis A.,University of Santa Maria in Ecuador |
And 18 more authors.
Orphanet Journal of Rare Diseases | Year: 2014
Background: Pompe's disease is a progressive myopathy caused by mutations in the lysosomal enzyme acid alphaglucosidase gene (GAA). A wide clinical variability occurs also in patients sharing the same GAA mutations, even within the same family.Methods. For a large series of GSDII patients we collected some clinical data as age of onset of the disease, presence or absence of muscular pain, Walton score, 6-Minute Walking Test, Vital Capacity, and Creatine Kinase. DNA was extracted and tested for GAA mutations and some genetic polymorphisms able to influence muscle properties (ACE, ACTN3, AGT and PPAR genes). We compared the polymorphisms analyzed in groups of patients with Pompe disease clustered for their homogeneous genotype.Results: We have been able to identify four subgroups of patients completely homogeneous for their genotype, and two groups homogeneous as far as the second mutation is defined "very severe" or "potentially less severe". When disease free life was studied we observed a high significant difference between groups. The DD genotype in the ACE gene and the XX genotype in the ACTN3 gene were significantly associated to an earlier age of onset of the disease. The ACE DD genotype was also associated to the presence of muscle pain.Conclusions: We demonstrate that ACE and ACTN3 polymorphisms are genetic factors able to modulate the clinical phenotype of patients affected with Pompe disease. © 2014 De Filippi et al.; licensee BioMed Central Ltd.